ABVC BioPharma (ABVC) Competitors $1.19 -0.18 (-13.14%) Closing price 04:00 PM EasternExtended Trading$1.20 +0.01 (+1.18%) As of 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABVC vs. ORMP, ANIX, CLLS, CLYM, SNTI, ADAG, GALT, PLRX, OCX, and ANROShould you be buying ABVC BioPharma stock or one of its competitors? The main competitors of ABVC BioPharma include Oramed Pharmaceuticals (ORMP), Anixa Biosciences (ANIX), Cellectis (CLLS), Climb Bio (CLYM), Senti Biosciences (SNTI), Adagene (ADAG), Galectin Therapeutics (GALT), Pliant Therapeutics (PLRX), OncoCyte (OCX), and Alto Neuroscience (ANRO). These companies are all part of the "pharmaceutical products" industry. ABVC BioPharma vs. Oramed Pharmaceuticals Anixa Biosciences Cellectis Climb Bio Senti Biosciences Adagene Galectin Therapeutics Pliant Therapeutics OncoCyte Alto Neuroscience Oramed Pharmaceuticals (NASDAQ:ORMP) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, community ranking, analyst recommendations, institutional ownership, media sentiment, risk and valuation. Does the MarketBeat Community favor ORMP or ABVC? Oramed Pharmaceuticals received 319 more outperform votes than ABVC BioPharma when rated by MarketBeat users. CompanyUnderperformOutperformOramed PharmaceuticalsOutperform Votes31971.85% Underperform Votes12528.15% ABVC BioPharmaN/AN/A Do institutionals & insiders hold more shares of ORMP or ABVC? 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 13.7% of Oramed Pharmaceuticals shares are owned by insiders. Comparatively, 11.9% of ABVC BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend ORMP or ABVC? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00ABVC BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher valuation & earnings, ORMP or ABVC? Oramed Pharmaceuticals has higher revenue and earnings than ABVC BioPharma. ABVC BioPharma is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOramed Pharmaceuticals$1.34M64.32$5.53M-$0.44-4.80ABVC BioPharma$508.38K39.26-$10.52M-$0.13-9.15 Is ORMP or ABVC more profitable? Oramed Pharmaceuticals has a net margin of 0.00% compared to ABVC BioPharma's net margin of -1,619.65%. Oramed Pharmaceuticals' return on equity of -7.27% beat ABVC BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets Oramed PharmaceuticalsN/A -7.27% -6.20% ABVC BioPharma -1,619.65%-104.94%-56.81% Which has more risk and volatility, ORMP or ABVC? Oramed Pharmaceuticals has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500. Comparatively, ABVC BioPharma has a beta of 0.06, indicating that its share price is 94% less volatile than the S&P 500. Does the media prefer ORMP or ABVC? In the previous week, Oramed Pharmaceuticals had 4 more articles in the media than ABVC BioPharma. MarketBeat recorded 5 mentions for Oramed Pharmaceuticals and 1 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 0.00 beat Oramed Pharmaceuticals' score of -0.75 indicating that ABVC BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oramed Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative ABVC BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryOramed Pharmaceuticals beats ABVC BioPharma on 13 of the 15 factors compared between the two stocks. Get ABVC BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABVC vs. The Competition Export to ExcelMetricABVC BioPharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.96M$6.52B$5.37B$8.38BDividend YieldN/A2.65%5.22%4.11%P/E Ratio-1.388.9226.8419.71Price / Sales39.26253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book1.176.466.794.50Net Income-$10.52M$143.98M$3.23B$248.18M7 Day Performance-18.49%3.04%4.07%1.14%1 Month Performance36.33%7.44%12.52%15.20%1 Year Performance10.19%-2.46%16.83%6.56% ABVC BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABVCABVC BioPharma0.1962 of 5 stars$1.19-13.1%N/A+26.9%$19.96M$508,384.00-1.3830Gap DownORMPOramed Pharmaceuticals1.7549 of 5 stars$2.13-0.7%N/A-9.3%$86.81M$1.34M19.3210Earnings ReportANIXAnixa Biosciences1.7313 of 5 stars$2.64-2.2%$9.00+240.9%-8.1%$85M$210,000.00-6.775CLLSCellectis2.9011 of 5 stars$1.53-1.6%$6.67+337.2%-48.1%$84.77M$47.63M-1.17290CLYMClimb Bio2.5919 of 5 stars$1.25-1.6%$10.00+700.0%N/A$84.47MN/A-0.599News CoverageEarnings ReportAnalyst RevisionSNTISenti Biosciences1.696 of 5 stars$3.20-1.2%$12.00+275.0%-14.9%$83.46M$2.56M-0.214ADAGAdagene2.319 of 5 stars$1.75-1.4%$8.00+358.5%-40.0%$82.21M$103,204.000.00260GALTGalectin Therapeutics1.2204 of 5 stars$1.29-3.0%$11.00+752.7%-59.2%$81.50MN/A-1.779Earnings ReportPLRXPliant Therapeutics4.2448 of 5 stars$1.33-1.9%$13.31+904.7%-90.9%$81.34M$1.58M-0.4090Positive NewsOCXOncoCyte2.4102 of 5 stars$2.80-0.1%$4.42+58.0%+6.5%$79.96M$3.84M-0.79120Analyst ForecastGap DownANROAlto Neuroscience1.7323 of 5 stars$2.95+15.9%$15.40+422.9%-76.5%$79.57MN/A-1.26N/ANews CoverageAnalyst Revision Related Companies and Tools Related Companies Oramed Pharmaceuticals Competitors Anixa Biosciences Competitors Cellectis Competitors Climb Bio Competitors Senti Biosciences Competitors Adagene Competitors Galectin Therapeutics Competitors Pliant Therapeutics Competitors OncoCyte Competitors Alto Neuroscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABVC) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABVC BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ABVC BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ABVC Stock Free ABVC Stock Alerts